Diabetic Gastroparesis Treatment Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Diabetes Prevalence and Complication Burden

Diabetic gastroparesis becomes more likely as diabetes duration increases, which enlarges the clinically relevant patient pool for the diabetic gastroparesis treatment market. A 2026 cross-sectional study of 485 patients found that diabetes lasting more than 10 years was associated with higher rates of impaired gastric emptying.^[1] This pattern matters because patients can develop substantial symptom burden before they receive a formal diagnosis. A 2025 study of 3,542 people with diabetes in Palestine found that only 1.9% of those whose symptom scores were consistent with gastroparesis had received a clinical diagnosis.^[2] The gap between symptoms and diagnosis leaves patients without a structured treatment pathway. As awareness improves, this group can enter specialist care and increase demand for medication, nutritional management, and procedural treatment.

Growing Diagnosis and Gastroenterology Specialty Care

Clearer diagnostic guidance can expand the treated population in the diabetic gastroparesis treatment market. The American Gastroenterological Association guideline published in 2025 recommends 4-hour gastric emptying scintigraphy instead of shorter testing protocols. The guideline reported that 4-hour testing can identify 25% more cases than 2-hour testing. It also conditionally supports metoclopramide and erythromycin as first-line treatment options. These recommendations give gastroenterologists a more consistent basis for diagnosis and prescribing. They also support specialist referral pathways when first-line treatment does not control symptoms.

Locally Acting Prokinetic Pipeline Advances

The diabetic gastroparesis treatment market has limited approved drug options, which increases interest in candidates designed to reduce systemic adverse effects. Naronapride is an orally administered, gut-restricted agent that combines 5-HT4 agonism with D2 receptor antagonism. Dr. Falk Pharma reported completion of enrollment for 320 patients in the MOVE-IT Phase 2b study in May 2025.^[3] The company stated that Phase 3 planning was underway after the study reached full enrollment. Deudomperidone was also being assessed as a modified molecule intended to address the cardiac liabilities associated with domperidone. These programs show how the diabetic gastroparesis treatment market may move toward therapies that aim to preserve prokinetic activity without relying on centrally active mechanisms.

Improved Oral and Nasal Delivery for Delayed Gastric Emptying

Patients with severe delayed gastric emptying can absorb oral medicines unpredictably, which limits the reliability of oral treatment when symptoms are most severe. This limitation creates room for delivery systems that bypass impaired gastric emptying. A 2025 real-world analysis of 372,700 patients with type 2 diabetes and gastroparesis associated intranasal metoclopramide with 30% fewer acute care episodes than oral metoclopramide. The same analysis reported a median time to first hospitalization of 12 months for intranasal treatment and 7 months for oral treatment. GIMOTI recorded USD 11.1 million in year-to-date net sales through the third quarter of 2025, an increase of 60% from the prior year. This commercial result shows the value that specialist practices may place on administration routes that better match the clinical limitations of gastroparesis.

Metoclopramide Neurologic Safety Constraints

Metoclopramide remains the central drug option in the diabetic gastroparesis treatment market, but its safety profile limits long-term use. The product class carries a 12-week use restriction and a boxed warning concerning tardive dyskinesia. A 2025 review of FDA Adverse Event Reporting System data found a reporting odds ratio of 499 for tardive dyskinesia with metoclopramide, with a confidence interval from 486 to 512. The study does not establish an absolute incidence rate, but it supports continued caution among prescribers. Safety concerns can limit persistence on therapy, especially for people with chronic symptoms. The absence of a broadly approved long-term drug alternative leaves clinicians to manage symptoms within a restricted treatment framework.

Diagnostic Heterogeneity and Delayed Treatment Initiation

Diagnostic inconsistency delays access to treatment in the diabetic gastroparesis treatment market. A 2026 study reported symptom-score-based prevalence of 20.8%, compared with 13.1% when gastric emptying scintigraphy confirmed the condition. The study found poor agreement between the two methods, with a Cohen's kappa value of 0.107. A 2025 motility clinic review found confirmed gastroparesis in 19.5% of referred patients, while 44.5% received a functional dyspepsia diagnosis. This uncertainty can postpone medication initiation, complicate reimbursement decisions, and reduce confidence in longer-duration procedural care.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Diabetic Gastroparesis Treatment Market Segment Analysis

Medication accounted for 76.03% of the diabetic gastroparesis treatment market share in 2026. The position reflects the usual practice of starting with pharmacological care before considering an intervention. Prokinetic agents, especially metoclopramide and erythromycin, remain important first-line treatments under the 2025 American Gastroenterological Association guideline. Antiemetics also remain important for managing nausea and vomiting. A 2025 analysis of emergency department encounters found that 5-HT3 antagonists, including ondansetron, were administered in 61.3% of gastroparesis-related visits. Antidepressants and neuromodulators have a narrower role because the guideline does not recommend nortriptyline as first-line therapy.

Surgery and Procedural Treatment is forecast to grow at an 8.01% CAGR through 2032 in the diabetic gastroparesis treatment market. This category is gaining relevance for people whose symptoms persist despite drug therapy. A multicenter study published in 2025 found that G-POEM reduced the Gastroparesis Cardinal Symptom Index by 37.2%. The study reported recurrence rates of 41.6% for G-POEM and 78.8% for gastric electrical stimulation. Medicare coverage for Enterra GES in the Ambulatory Surgical Center setting began in January 2026. The national average payments were USD 16,244 for the neurostimulator and USD 9,997 for leads. This coverage can support procedural adoption outside hospital operating rooms.

Oral formulations held a 68.83% share in 2026. Their lead reflects established prescribing patterns and broad formulary availability across drug classes. Oral medicines remain appropriate for patients who can maintain reliable absorption. However, delayed gastric emptying can make absorption unpredictable, particularly in severe disease. This creates a mismatch between the route of administration and the condition being treated. Autonomic neuropathy can compound this problem by increasing variation in gastric motility. The diabetic gastroparesis treatment industry therefore needs routes that provide more predictable exposure when oral dosing is unreliable.

Injectables are forecast to grow at an 8.53% CAGR through 2032. Their use includes botulinum toxin injections directed at pyloric dysfunction and subcutaneous metoclopramide in acute care. Injectable prokinetic candidates could broaden this route if they progress through clinical development. Nasal delivery is a separate non-oral option with early clinical and commercial relevance. The real-world study of intranasal metoclopramide showed fewer acute care episodes than oral administration in adults with type 2 diabetes and gastroparesis. The route may be most relevant for patients with symptomatic delayed emptying who require consistent exposure. Its uptake depends on specialist prescribing, coverage, and evidence that it improves care beyond conventional oral therapy.

Moderate-to-Severe Gastroparesis commanded a 47.16% share in 2026. This group accounts for a large share of medicine use because clinicians commonly stabilize symptoms before escalating care. Prokinetics and antiemetics are central to symptom control in this setting. Patients with this severity level also form the principal target population for device treatment and newer pharmacological candidates. Naronapride and deudomperidone enrolled patients with moderate-to-severe symptoms in their Phase 2 programs. The group therefore connects the established medication base with the pipeline for alternatives that may be used if conventional options are insufficient.

Refractory Gastroparesis is forecast to grow at an 8.63% CAGR through 2032. These patients are more likely to be considered for specialized procedures after medication does not provide durable symptom control. A 2025 network meta-analysis of 55 studies reported that G-POEM had the greatest short-term symptom benefit among evaluated interventions. The same analysis found that gastric electrical stimulation had the highest efficacy at intermediate follow-up beyond 3 months. These findings support a staged approach rather than a single fixed intervention. Compensated gastroparesis remains more likely to be managed through dietary changes and low-dose prokinetics. That limits branded medicine and procedure use in the mildest severity group.

Type 2 Diabetes-Associated Gastroparesis held an 82.63% share in 2026. This reflects the much larger global population living with type 2 diabetes than type 1 diabetes. A 2025 review reported that gastroparesis develops in both diabetes types, although the published 10-year cumulative incidence was higher in type 1 diabetes. Type 2 diabetes nevertheless supplies the larger absolute pool of potential patients. Symptom prevalence can exceed formal diagnosis rates, especially after long diabetes duration. Earlier recognition of symptoms may therefore increase the number of people entering pharmacological and specialist care.

Post-Surgical Diabetic Gastroparesis is forecast to grow at an 8.28% CAGR through 2032. This category is associated with the rising use of bariatric and metabolic surgery among people with type 2 diabetes. Anatomical changes after sleeve gastrectomy, gastric bypass, or distal gastrectomy can make standard gastric emptying criteria difficult to apply. This complexity can delay recognition of postoperative delayed gastric emptying. It can also make symptom interpretation more difficult for treating clinicians. No approved therapy carries a specific indication for this subgroup. This leaves a treatment gap for companies that can develop evidence relevant to post-surgical disease.

Hospitals held a 53.92% share in 2026. Their lead reflects acute presentations that require hydration, control of severe nausea, nutrition support, and procedural resources. A 2025 retrospective study of 406 patients found that 23% experienced hospitalizations during the year. The study also reported higher inpatient use among people with diabetic gastroparesis. Hospitals remain necessary for complex cases and device implantation. However, the extension of GES coverage to the Ambulatory Surgical Center setting can move some procedures into lower-cost outpatient facilities.

Specialty Clinics are forecast to grow at a 7.76% CAGR through 2032. This growth reflects the expansion of gastroenterology and motility-focused care pathways. Large multi-site gastroenterology practices are developing more concentrated routes for patients with motility disorders. The 2025 American Gastroenterological Association guideline supports referral to specialists when first-line treatment is unsuccessful. Clinics can coordinate diagnostic testing, medication adjustment, nutrition advice, and referral for intervention. They may also be better positioned to evaluate new delivery routes and pipeline treatments. The growing specialty-clinic footprint can make care more structured while reducing unnecessary dependence on acute hospital services.

Geography Analysis

North America

North America held 42.31% of the diabetic gastroparesis treatment market share in 2026. The region has a dense base of gastroenterology and motility specialists, as well as a developed reimbursement framework for medication and procedures. The American Gastroenterological Association cited a United States prevalence of 21 to 24 cases per 100,000 people. The same guidance noted that women represent 75% of diagnosed cases. Medicare coverage of Enterra GES in Ambulatory Surgical Centers took effect in January 2026 and expanded access outside hospital operating rooms. The region also benefits from the availability of FDA-approved metoclopramide formulations and a pipeline that includes differentiated prokinetic candidates.

Asia-Pacific

Asia-Pacific is forecast to grow at a 9.26% CAGR through 2032, the fastest rate among geographic segments in the diabetic gastroparesis treatment market. Growth reflects expanding diabetes populations, higher health spending, and improving access to diagnostic services. Longer diabetes duration, female sex, and poor glycemic control are associated with delayed gastric emptying in a type 2 diabetes cohort from India. Specialist capacity remains limited in many parts of the region, which can leave a large number of patients untreated. Greater use of structured testing and gastroenterology referral could improve identification of symptomatic patients. Reimbursement support for complex medication regimens in South Korea also indicates a more receptive setting for specialist-directed care.

Europe, Middle East and Africa, and South America

Europe is supported by established healthcare systems in Germany, the United Kingdom, and France, where a 2025 consensus framework helped formalize structured gastroparesis management. This gives clinicians a basis to consider care beyond metoclopramide monotherapy. Middle East and Africa have an emerging patient pool as investment in gastroenterology capacity expands in Gulf Cooperation Council countries. A 2025 study in Palestine reported untreated gastroparetic symptoms in 14.5% of people with type 2 diabetes. The finding indicates a sizable diagnostic gap where specialist access remains limited. South America is led by Brazil and Argentina, where generic metoclopramide is available through public-sector channels. Private care may create an early opportunity for reformulated therapies, although broad uptake will depend on affordability and physician access. Across these mixed regions, the diabetic gastroparesis treatment market will expand as diagnostic protocols, specialist care, and reimbursement mature at different speeds.